Allogene Therapeutics, Inc.

Contributing Author

Recent Articles by Allogene Therapeutics, Inc.

Feb-05	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences ALLO -9.44% GlobeNewswire
Jan-08	Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T ALLO GlobeNewswire
Dec-15	Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis ALLO GlobeNewswire
Nov-10	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences ALLO GlobeNewswire
Nov-06	Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update ALLO +12.38% ALLO -5.41% GlobeNewswire
Nov-03	Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting ALLO GlobeNewswire
Oct-30	Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update ALLO GlobeNewswire
Aug-27	Allogene Therapeutics Announces Participation in Upcoming Investor Conference ALLO GlobeNewswire
Aug-13	Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update ALLO GlobeNewswire
Aug-06	Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update ALLO -5.36% GlobeNewswire
Aug-01	Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma ALLO -12.20% GlobeNewswire
Jun-01	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO ALLO GlobeNewswire
May-23	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences ALLO GlobeNewswire
May-22	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel ALLO GlobeNewswire
May-13	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update ALLO -15.68% ALLO GlobeNewswire
May-06	Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ALLO -20.99% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.